含硼替佐米的化疗方案对多发性骨髓瘤患者的效果与不良反应研究  

Clinical efficacy and adverse effects of containing bortezomib chemotherapy in treatment of multiple myeloma

作　　者：罗泉芳[1] 王薇[1] 陈钦玭 庞爱萍 LUO Quanfang;WANG Wei;CHEN Qinli(Department of Hematology,Nanxishan Hospital,Guangxi Zhuang Autonomous Region,Guilin 451002,China)

机构地区：[1]广西壮族自治区南溪山医院血液科,广西壮族自治区桂林市451002

出　　处：《河北医药》2020年第9期1379-1382,共4页Hebei Medical Journal

摘　　要：目的评价含硼替佐米的化疗方案对多发性骨髓瘤患者的临床效果与不良反应。方法选择2015年4月至2018年4月住院治疗的52例多发性骨髓瘤患者,根据治疗方案分为观察组和对照组,每组26例。观察组采用BCD(硼替佐米+地塞米松+环磷酰胺)方案,对照组采用常规(硫酸长春新碱+地塞米松+盐酸表柔比星)方案,分别按照方案设定条件,以28 d为1个疗程,连续治疗3个疗程。比较2组患者的短效疗效及总体反应率(ORR)、生存分析及总生存期(OS)和无进展生存期(PFS)、免疫抑制因子和淋巴细胞水平变化、不良反应发生情况等。结果观察组的ORR为84.6%显著高于对照组的57.7%(P<0.05);观察组的中位OS和PFS显著高于对照组(P<0.05);观察组的免疫抑制因子(IL-6、IL-7、TGF-β)、淋巴细胞(CD+3CD+4、CD+3CD+8和CD+3CD+4/CD+3CD+8)改善程度显著优于对照组(P<0.05);观察组不良反应发生率显著优于对照组(P<0.05)。结论含硼替佐米的化疗方案针对于多发性骨髓瘤患者的临床效果确切,安全性良好,可以有效延长患者的生存周期,提高免疫能力。Objective To investigate the therapeutic effects and adverse effects of containing bortezomib chemotherapy in treatment of multiple myeloma(MM).Methods A total of 52 patient with MM who were treated in our hospital from April 2014 to April 2017 were enrolled in the study,who were divided into observation group and control group according to different treatment schemes,with 26 cases in each group.The patients in observation group were treated by BCD scheme(bortezomib+dexamethasone+cyclophosphamide),however,thepatients in control group were treated by the treatment scheme(vincristine sulfate+dexamethasone+epirubicin hydrochloride),with a treatment course of 28 days,for three consecutive treatment courses.The short-term curative effects and overall reaction rate(ORR),survival analysis(OS and PFS),immunosuppressive factors and lymphocyte level changes,and the incidence of adverse reactions were observed and compared between the two groups.Results After 3-treatment courses,the ORR in observation group was 84.6%,which was significantly higher than that(57.7%)in control group(P<0.05).The median OS and PFS in observation group were significantly higher than those in control group(P<0.05).Moreover the improvement degree of immunosuppressive factors(Il-6,Il-7,TGF-β)and lymphocytes(CD+3CD+4,CD+3CD+8 and CD+3CD+4/CD+3CD+8)in observation group was more significant than that in control group(P<0.05),and the incidence rate of adverse reactions in observation group was significantly lower than that in control group(P<0.05).Conclusion The chemotherapy regimen containing bortezomib has definite clinical effects and good safety in treatment of MM,which can effectively prolong the life cycle of patients and improve the immune function of patients.

关 键 词：硼替佐米 多发性骨髓瘤 化疗方案 治疗结果 不良反应 

分 类 号：R733.3[医药卫生—肿瘤]